针对神经生长因子介导的骨质肉瘤转移:使用larotrectinib的机制性见解和治疗机会
Chun-Han Hou1, Wei-Li Chen2, Chih-Yang Lin3
1Department of Orthopedic Surgery, National Taiwan University Hospital, No. 1, Jen-Ai Road, Taipei, 100, Taiwan, ROC.
Cell death & disease
|May 30, 2024
概括
神经生长因子 (NGF) 通过增加MMP-2通过MEK/ERK通路的表达来驱动骨肉瘤转移,提供潜在的治疗点. 拉罗特雷克提尼布在抑制这一过程方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症转移研究 癌症转移研究
背景情况:
- 骨髓瘤 (OS) 的生存率很低,特别是在转移后.
- 神经生长因子 (NGF) 与各种癌症的转移有关,但其在骨髓瘤中的作用尚不清楚.
研究的目的:
- 研究NGF在骨髓瘤细胞迁移和转移中的作用.
- 为了阐明NGF介导的骨肉瘤进展背后的分子机制.
主要方法:
- 来自TARGET-OS数据库的RNA测序和基因表达数据的分析.
- 使用来自骨髓瘤患者的骨组织阵列进行验证.
- 使用人类骨髓瘤细胞 (143B,MG63) 的体外研究以及体内 ортотоп性小鼠模型.
- 研究MEK/ERK信号通路和microRNA-92a-1-5p (miR-92a-1-5p) 的参与.
- 测试拉罗特雷克提尼布的疗效.
主要成果:
- 在骨髓瘤组织中,NGF表达显著更高,与瘤阶段相关.
- NGF上调矩阵金属酶-2 (MMP-2) 表达,促进细胞迁移,入侵和转移.
- NGF激活了MEK/ERK信号通路,并降低了miR-92a-1-5p水平.
- 拉罗特雷克提尼布在体内显著抑制NGF诱导的肺转移.
结论:
- NGF通过MEK/ERK通路调节MMP-2并抑制miR-92a-1-5p,从而促进骨髓瘤转移.
- 向NGF,特别是用larotrectinib,为骨髓瘤转移提供了一个潜在的治疗策略.
更多相关视频
04:25Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
9.1K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K